Peptide Lab HQ Research Guide
Prostamax
A research-focused compound profile covering Prostamax identity, KEDP tetrapeptide research, prostate tissue model context, peptide bioregulator research, concentration reference, preparation reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | Prostamax |
|---|---|
| Common Research Name | KEDP tetrapeptide |
| Common Synonyms | Lys-Glu-Asp-Pro, Lysyl-glutamyl-aspartyl-proline, KEDP peptide, SCHEMBL6660498 |
| Compound Type | Synthetic ultrashort tetrapeptide / peptide bioregulator research compound |
| CAS Number | Commonly listed as 473578-47-1 or 2259884-03-0 depending on reference; verify against supplier COA |
| PubChem CID | 9848296 |
| Amino Acid Length | 4 amino acids |
| Amino Acid Sequence | Lys-Glu-Asp-Pro |
| Short Sequence | KEDP |
| Molecular Formula | C₂₀H₃₃N₅O₉; verify against supplier COA |
| Molecular Weight | Approximately 487.5 g/mol; verify against supplier COA |
| Research Category | Peptide bioregulator, prostate tissue model, prostatotropic research, inflammatory-response, cellular remodeling, gene-expression, and aging-marker research |
| Research Context | Commonly discussed in ultrashort peptide bioregulator research involving prostate tissue models, inflammatory-response pathways, tissue remodeling, and tissue-specific regulatory signaling. |
| Appearance | White to off-white lyophilized powder, depending on supplier documentation |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
Prostamax is commonly discussed in controlled research models involving KEDP tetrapeptide activity, prostate tissue response, peptide bioregulation, inflammatory-response pathways, stromal remodeling, epithelial tissue observations, and tissue-specific regulatory signaling.
Peptide Bioregulator Research
Prostamax is commonly positioned within ultrashort peptide bioregulator research, where short amino acid sequences are studied for tissue-specific signaling and gene-expression related effects.
Prostate Tissue Models
Prostamax has been evaluated in experimental prostate tissue models involving chronic aseptic inflammatory response, tissue density, and histological changes.
Inflammatory-Response Research
Published animal research has discussed Prostamax in relation to swelling, vascular hyperemia, lymphoid infiltration, and inflammatory tissue-response markers.
Stromal Remodeling Context
Research models have evaluated connective-tissue changes, collagen fiber area, sclerotic processes, and tissue remodeling in prostate gland observations.
Epithelial Tissue Research
Prostamax research has included epithelial-area observations in prostate gland models, particularly in relation to atrophic-process documentation.
Gene-Expression Context
Short peptide bioregulator research is commonly discussed around tissue-specific regulation, biosynthesis, transcriptional activity, and cellular renewal models.
Research Scope
These applications are provided for educational and research-reference purposes only. Prostamax research is limited compared with major peptide categories, and outcomes may vary based on sequence identity, purity, study model, concentration, exposure duration, tissue model, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Quick Reference Summary
| Reference Vial | 20 mg Prostomax |
|---|---|
| Primary Solution Volume | 1.0 mL bacteriostatic water |
| Primary Concentration | 20 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 20 mg/mL, 1 unit equals 0.2 mg / 200 mcg Prostomax. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 1.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear to slightly hazy depending on concentration and supplier format. Do not shake!
- Because this is a concentrated 20 mg/mL preparation, verify complete dissolution before recording final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | Prostomax, commonly referenced in research-catalog contexts as Prostamax / KEDP / Lys-Glu-Asp-Pro | Prostomax is commonly discussed as a synthetic tetrapeptide bioregulator associated with prostate-focused cellular and tissue-response research contexts. |
| Peptide Bioregulator Research | Model-dependent concentration and endpoint tracking | Commonly discussed in short-peptide bioregulator, chromatin-organization, gene-expression, cellular-response, and tissue-specific regulatory research contexts. |
| Prostate Tissue Research Context | Experimental prostate-cell and prostate-tissue model context | Prostomax / Prostamax-style references commonly focus on prostate-cell models, prostate-tissue response, age-associated tissue markers, cellular metabolism, and functional tissue-integrity observations. |
| Inflammatory-Marker Research | Experimental and model-dependent context | Research references commonly discuss inflammatory-marker response, tissue swelling markers, vascular-response markers, lymphoid-infiltration context, and prostate-associated inflammatory models. |
| Gene-Expression / Epigenetic Research Context | Short peptide / chromatin interaction context | Short peptide bioregulator literature commonly discusses DNA interaction, chromatin structure, regulatory sequence context, and changes in gene-expression marker patterns depending on the model. |
| Public Protocol-Style Reference | Milligram-range reference examples | Public protocol-style references commonly describe Prostomax / Prostamax in milligram-range examples. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, public protocol-style references, wellness protocols, or public dosing pages should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 20 mg | 1.0 mL | 20 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 20 mg/mL | U-100 Unit Reference | Approx. References per 20 mg Vial |
|---|---|---|---|
| 0.5 mg / 500 mcg | 0.025 mL | 2.5 units | 40 |
| 1 mg / 1000 mcg | 0.05 mL | 5 units | 20 |
| 2 mg / 2000 mcg | 0.10 mL | 10 units | 10 |
| 5 mg / 5000 mcg | 0.25 mL | 25 units | 4 |
| 10 mg / 10000 mcg | 0.50 mL | 50 units | 2 |
| 20 mg / 20000 mcg | 1.00 mL | 100 units | 1 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.5 mg reference amount | 2.5 units / 0.025 mL |
| Standard Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 1 mg reference amount | 5 units / 0.05 mL |
| Mid-Range Conversion Example | Calculation reference only | 2 mg reference amount | 10 units / 0.10 mL |
| Upper Conversion Example | Calculation reference only | 5 mg reference amount | 25 units / 0.25 mL |
| High Conversion Example | Calculation reference only | 10 mg reference amount | 50 units / 0.50 mL |
| Full-Vial Preparation Reference | Preparation-level calculation reference | 20 mg reference amount | 100 units / 1.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Marker Observation Window | 24–72 hours | May be used for gene-expression, chromatin-organization, inflammatory-marker, prostate-cell response, cellular-aging marker, or peptide-response documentation depending on the model. |
| Acute Observation Window | Single session to several days | Used for early response tracking, cellular-marker comparison, inflammatory-marker observation, or short-term pathway documentation depending on the research design. |
| Short Research Window | 1–2 weeks | May be used for short-duration controlled observation involving prostate-associated cellular response, tissue-integrity markers, inflammatory markers, or gene-expression endpoints. |
| Standard Protocol-Style Window | 2–4 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 4–8 weeks | Used when longer documentation is needed for prostate-associated marker trends, tissue-response context, cellular-aging markers, or follow-up marker tracking. |
| Follow-Up / Washout | 1–4 weeks | Used to document post-study observations, marker return, delayed response patterns, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. Prostomax, commonly referenced in research-catalog contexts as Prostamax / KEDP / Lys-Glu-Asp-Pro, is discussed in peptide bioregulator, prostate-associated tissue-response, inflammatory-marker, chromatin-organization, gene-expression, cellular-aging marker, and tissue-specific regulatory research contexts. This reference uses a 20 mg vial reconstituted with 1.0 mL bacteriostatic water, creating a 20 mg/mL concentration. Higher-concentration preparations may require supplier-specific handling, solvent-volume, or solubility notes; verify against the COA, batch record, or formula record when available. Published study references and public protocol-style frequency references are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
Prostamax is commonly discussed in research involving ultrashort peptide bioregulation, KEDP tetrapeptide signaling, prostate tissue model context, chronic aseptic inflammatory-response observations, stromal remodeling, epithelial tissue response, and tissue-specific regulatory pathways.
Study Limitations
Prostamax research is limited compared with major peptide categories and includes peptide bioregulator, prostate tissue, animal inflammatory-model, and histological research references. Findings should be interpreted according to peptide sequence, purity, model type, concentration, exposure duration, and endpoint selection.
Safety Considerations
Research discussion should account for peptide identity verification, KEDP sequence confirmation, sterility documentation, endotoxin risk, supplier qualification, batch records, storage conditions, and qualified laboratory handling procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.